UroGen Pharma Ltd. (URGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 70M 140M 210M Q4 '17: 8.2M Q1 '18: 8.6M Q2 '18: 9M Q3 '18: 1.5M Q4 '18: 1.1M Q1 '19: 647K Q2 '19: 301K Q3 '19: 18K Q4 '19: 18K Q1 '21: 19.3M Q2 '21: 31.9M Q3 '21: 39.8M Q4 '21: 48M Q1 '22: 54.1M Q2 '22: 57.7M Q3 '22: 62.4M Q4 '22: 64.4M Q1 '23: 68M Q2 '23: 72.5M Q3 '23: 77.3M Q4 '23: 82.7M Q1 '24: 84.3M Q2 '24: 85M Q3 '24: 89.4M Q4 '24: 90.4M Q1 '25: 91.9M Q2 '25: 94.2M Q3 '25: 96.5M Q4 '25: 109.8M Q1 '26: 140.5M Q2 '26: 188.7M Q2 '18 Q2 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

-60M 0 60M 120M 180M Q4 '17: 7.6M Q1 '18: 7.6M Q2 '18: 7.7M Q3 '18: -635K Q4 '18: -675K Q1 '19: -726K Q2 '19: -754K Q3 '19: 18K Q4 '19: 18K Q1 '21: 17.4M Q2 '21: 28.7M Q3 '21: 35.6M Q4 '21: 42.9M Q1 '22: 48.3M Q2 '22: 51.5M Q3 '22: 55.5M Q4 '22: 56.7M Q1 '23: 59.6M Q2 '23: 63.5M Q3 '23: 67.9M Q4 '23: 73.4M Q1 '24: 75.5M Q2 '24: 76.4M Q3 '24: 80.7M Q4 '24: 81.5M Q1 '25: 82.4M Q2 '25: 83.4M Q3 '25: 84.9M Q4 '25: 97.3M Q1 '26: 126.2M Q2 '26: 171.5M Q2 '18 Q2 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '17: -19.9M Q1 '18: -30.1M Q2 '18: -42.5M Q3 '18: -63.3M Q4 '18: -77.2M Q1 '19: -86M Q2 '19: -91.3M Q3 '19: -93.7M Q4 '19: -109.5M Q1 '20: -125.6M Q2 '20: -133.7M Q3 '20: -139.3M Q4 '20: -126.7M Q1 '21: -114.3M Q2 '21: -105.3M Q3 '21: -99.6M Q4 '21: -92.3M Q1 '22: -88.1M Q2 '22: -84M Q3 '22: -78.7M Q4 '22: -79M Q1 '23: -79.1M Q2 '23: -75.8M Q3 '23: -71.2M Q4 '23: -65.5M Q1 '24: -69.2M Q2 '24: -79.7M Q3 '24: -83.7M Q4 '24: -96.8M Q1 '25: -108M Q2 '25: -123.6M Q3 '25: -133.4M Q4 '25: -124.9M Q1 '26: -108.2M Q2 '26: -66.7M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-180M -120M -60M 0 60M 120M 180M Q4 '17: -20M Q1 '18: -30M Q2 '18: -41.8M Q3 '18: -62M Q4 '18: -75.7M Q1 '19: -83.7M Q2 '19: -88.2M Q3 '19: -89.9M Q4 '19: -105.1M Q1 '20: -121.5M Q2 '20: -130.4M Q3 '20: -136.9M Q4 '20: -128.5M Q1 '21: -116.6M Q2 '21: -111.5M Q3 '21: -112.9M Q4 '21: -110.8M Q1 '22: -113.3M Q2 '22: -113.7M Q3 '22: -109.4M Q4 '22: -109.8M Q1 '23: -111.6M Q2 '23: -109M Q3 '23: -105.1M Q4 '23: -102.2M Q1 '24: -104.3M Q2 '24: -113.6M Q3 '24: -115.4M Q4 '24: -126.9M Q1 '25: -138.4M Q2 '25: -155M Q3 '25: -164.6M Q4 '25: -153.5M Q1 '26: -133.2M Q2 '26: -97.6M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 6M 12M 18M Q4 '17: 600K Q1 '18: 1M Q2 '18: 1.3M Q3 '18: 2.1M Q4 '18: 1.8M Q1 '21: 1.9M Q2 '21: 3.3M Q3 '21: 4.2M Q4 '21: 5.2M Q1 '22: 5.8M Q2 '22: 6.2M Q3 '22: 7M Q4 '22: 7.7M Q1 '23: 8.4M Q2 '23: 9M Q3 '23: 9.3M Q4 '23: 9.4M Q1 '24: 8.8M Q2 '24: 8.6M Q3 '24: 8.7M Q4 '24: 8.9M Q1 '25: 9.5M Q2 '25: 10.8M Q3 '25: 11.6M Q4 '25: 12.4M Q1 '26: 14.3M Q2 '26: 17.3M Q2 '18 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q4 '17: -9.6M Q1 '18: -16.4M Q2 '18: -21.1M Q3 '18: -33M Q4 '18: -37.3M Q1 '19: -45.6M Q2 '19: -52.1M Q3 '19: -55.3M Q4 '19: -71M Q1 '20: -88.7M Q2 '20: -98.1M Q3 '20: -110.6M Q4 '20: -105.9M Q1 '21: -97.7M Q2 '21: -92.7M Q3 '21: -86.1M Q4 '21: -84.9M Q1 '22: -81.5M Q2 '22: -86.7M Q3 '22: -85.9M Q4 '22: -87.6M Q1 '23: -89.4M Q2 '23: -85.4M Q3 '23: -85.1M Q4 '23: -76.4M Q1 '24: -82.3M Q2 '24: -85.8M Q3 '24: -96.1M Q4 '24: -96.8M Q1 '25: -107.1M Q2 '25: -123.1M Q3 '25: -137.7M Q4 '25: -162.4M Q1 '26: -165.7M Q2 '26: -158.9M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q4 '17: -9.8M Q1 '18: -16.7M Q2 '18: -21.5M Q3 '18: -33.7M Q4 '18: -37.9M Q1 '19: -46.2M Q2 '19: -52.5M Q3 '19: -55.5M Q4 '19: -71.3M Q1 '20: -89.1M Q2 '20: -98.7M Q3 '20: -111.9M Q4 '20: -107.1M Q1 '21: -99.1M Q2 '21: -93.9M Q3 '21: -86.8M Q4 '21: -85.6M Q1 '22: -82M Q2 '22: -87.2M Q3 '22: -86.3M Q4 '22: -87.8M Q1 '23: -89.6M Q2 '23: -85.6M Q3 '23: -85.3M Q4 '23: -76.6M Q1 '24: -82.5M Q2 '24: -86M Q3 '24: -96.4M Q4 '24: -97.1M Q1 '25: -107.4M Q2 '25: -123.5M Q3 '25: -138.1M Q4 '25: -162.7M Q1 '26: -166M Q2 '26: -159.1M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '21: 22.2M Q2 '21: 22.3M Q3 '21: 22.4M Q1 '22: 22.6M Q2 '22: 22.7M Q3 '22: 22.8M Q1 '23: 23.3M Q2 '23: 23.5M Q3 '23: 32.3M Q4 '23: 36.2M Q1 '24: 37.1M Q2 '24: 40.5M Q3 '24: 46.8M Q4 '24: 47M Q1 '25: 47.4M Q2 '25: 47.7M Q3 '25: 48.1M Q1 '26: 50.2M Q2 '26: 50.4M Q1 '21 Q1 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '17: -3.20 Q1 '18: -0.58 Q2 '18: -1.02 Q3 '18: -2.28 Q4 '18: -3.00 Q1 '19: -2.77 Q2 '19: -2.71 Q3 '19: -2.49 Q4 '19: -2.89 Q1 '20: -5.79 Q2 '20: -6.15 Q3 '20: -6.40 Q4 '20: -5.92 Q1 '21: -5.30 Q2 '21: -5.03 Q3 '21: -5.07 Q4 '21: -4.96 Q1 '22: -5.04 Q2 '22: -5.05 Q3 '22: -4.83 Q4 '22: -4.81 Q1 '23: -4.86 Q2 '23: -4.71 Q3 '23: -4.26 Q4 '23: -3.73 Q1 '24: -3.30 Q2 '24: -3.09 Q3 '24: -2.92 Q4 '24: -3.00 Q1 '25: -3.05 Q2 '25: -3.28 Q3 '25: -3.46 Q4 '25: -3.19 Q1 '26: -2.74 Q2 '26: -1.97 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.